234 related articles for article (PubMed ID: 31718704)
21. Antimyeloma activity of bromodomain inhibitors on the human myeloma cell line U266 by downregulation of MYCL.
Suzuki K; Yamamoto K; Arakawa Y; Yamada H; Aiba K; Kitagawa M
Anticancer Drugs; 2016 Sep; 27(8):756-65. PubMed ID: 27276402
[TBL] [Abstract][Full Text] [Related]
22. Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation.
Zhang P; Wang D; Zhao Y; Ren S; Gao K; Ye Z; Wang S; Pan CW; Zhu Y; Yan Y; Yang Y; Wu D; He Y; Zhang J; Lu D; Liu X; Yu L; Zhao S; Li Y; Lin D; Wang Y; Wang L; Chen Y; Sun Y; Wang C; Huang H
Nat Med; 2017 Sep; 23(9):1055-1062. PubMed ID: 28805822
[TBL] [Abstract][Full Text] [Related]
23. β2-adrenergic receptor signaling promotes pancreatic ductal adenocarcinoma (PDAC) progression through facilitating PCBP2-dependent c-myc expression.
Wan C; Gong C; Zhang H; Hua L; Li X; Chen X; Chen Y; Ding X; He S; Cao W; Wang Y; Fan S; Xiao Y; Zhou G; Shen A
Cancer Lett; 2016 Apr; 373(1):67-76. PubMed ID: 26803058
[TBL] [Abstract][Full Text] [Related]
24. Regulation of GLI Underlies a Role for BET Bromodomains in Pancreatic Cancer Growth and the Tumor Microenvironment.
Huang Y; Nahar S; Nakagawa A; Fernandez-Barrena MG; Mertz JA; Bryant BM; Adams CE; Mino-Kenudson M; Von Alt KN; Chang K; Conery AR; Hatton C; Sims RJ; Fernandez-Zapico ME; Wang X; Lillemoe KD; Fernández-Del Castillo C; Warshaw AL; Thayer SP; Liss AS
Clin Cancer Res; 2016 Aug; 22(16):4259-70. PubMed ID: 27169995
[TBL] [Abstract][Full Text] [Related]
25. PES1 enhances proliferation and tumorigenesis in hepatocellular carcinoma via the PI3K/AKT pathway.
Wang J; Sun J; Zhang N; Yang R; Li H; Zhang Y; Chen K; Kong D
Life Sci; 2019 Feb; 219():182-189. PubMed ID: 30630006
[TBL] [Abstract][Full Text] [Related]
26. The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors.
Wong C; Laddha SV; Tang L; Vosburgh E; Levine AJ; Normant E; Sandy P; Harris CR; Chan CS; Xu EY
Cell Death Dis; 2014 Oct; 5(10):e1450. PubMed ID: 25299775
[TBL] [Abstract][Full Text] [Related]
27. The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models.
Garcia PL; Miller AL; Kreitzburg KM; Council LN; Gamblin TL; Christein JD; Heslin MJ; Arnoletti JP; Richardson JH; Chen D; Hanna CA; Cramer SL; Yang ES; Qi J; Bradner JE; Yoon KJ
Oncogene; 2016 Feb; 35(7):833-45. PubMed ID: 25961927
[TBL] [Abstract][Full Text] [Related]
28. Increased Serotonin Signaling Contributes to the Warburg Effect in Pancreatic Tumor Cells Under Metabolic Stress and Promotes Growth of Pancreatic Tumors in Mice.
Jiang SH; Li J; Dong FY; Yang JY; Liu DJ; Yang XM; Wang YH; Yang MW; Fu XL; Zhang XX; Li Q; Pang XF; Huo YM; Li J; Zhang JF; Lee HY; Lee SJ; Qin WX; Gu JR; Sun YW; Zhang ZG
Gastroenterology; 2017 Jul; 153(1):277-291.e19. PubMed ID: 28315323
[TBL] [Abstract][Full Text] [Related]
29. PES1 is transcriptionally regulated by BRD4 and promotes cell proliferation and glycolysis in hepatocellular carcinoma.
Fan P; Wang B; Meng Z; Zhao J; Jin X
Int J Biochem Cell Biol; 2018 Nov; 104():1-8. PubMed ID: 30172011
[TBL] [Abstract][Full Text] [Related]
30. OLR1 Promotes Pancreatic Cancer Metastasis via Increased c-Myc Expression and Transcription of HMGA2.
Yang G; Xiong G; Feng M; Zhao F; Qiu J; Liu Y; Cao Z; Wang H; Yang J; You L; Zheng L; Zhang T; Zhao Y
Mol Cancer Res; 2020 May; 18(5):685-697. PubMed ID: 32019809
[TBL] [Abstract][Full Text] [Related]
31. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
Hari Y; Harashima N; Tajima Y; Harada M
Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
[TBL] [Abstract][Full Text] [Related]
32. Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma.
Bolin S; Borgenvik A; Persson CU; Sundström A; Qi J; Bradner JE; Weiss WA; Cho YJ; Weishaupt H; Swartling FJ
Oncogene; 2018 May; 37(21):2850-2862. PubMed ID: 29511348
[TBL] [Abstract][Full Text] [Related]
33. Loss of FBXW7-mediated degradation of BRAF elicits resistance to BET inhibitors in adult T cell leukemia cells.
Yeh CH; Bellon M; Wang F; Zhang H; Fu L; Nicot C
Mol Cancer; 2020 Sep; 19(1):139. PubMed ID: 32907612
[TBL] [Abstract][Full Text] [Related]
34. KIF3B Promotes the Proliferation of Pancreatic Cancer.
Liu ZH; Dong SX; Jia JH; Zhang ZL; Zhen ZG
Cancer Biother Radiopharm; 2019 Aug; 34(6):355-361. PubMed ID: 31157987
[No Abstract] [Full Text] [Related]
35. Targeting bromodomain-containing protein 4 (BRD4) inhibits MYC expression in colorectal cancer cells.
Otto C; Schmidt S; Kastner C; Denk S; Kettler J; Müller N; Germer CT; Wolf E; Gallant P; Wiegering A
Neoplasia; 2019 Nov; 21(11):1110-1120. PubMed ID: 31734632
[TBL] [Abstract][Full Text] [Related]
36. Loss of TRIM33 causes resistance to BET bromodomain inhibitors through MYC- and TGF-β-dependent mechanisms.
Shi X; Mihaylova VT; Kuruvilla L; Chen F; Viviano S; Baldassarre M; Sperandio D; Martinez R; Yue P; Bates JG; Breckenridge DG; Schlessinger J; Turk BE; Calderwood DA
Proc Natl Acad Sci U S A; 2016 Aug; 113(31):E4558-66. PubMed ID: 27432991
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathological and Preclinical Findings of NUT Carcinoma: A Multicenter Study.
Jung M; Kim S; Lee JK; Yoon SO; Park HS; Hong SW; Park WS; Kim JE; Kim J; Keam B; Kim HJ; Kang HJ; Kim DW; Jung KC; Kim YT; Heo DS; Kim TM; Jeon YK
Oncologist; 2019 Aug; 24(8):e740-e748. PubMed ID: 30696721
[TBL] [Abstract][Full Text] [Related]
38. CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer.
McCleland ML; Mesh K; Lorenzana E; Chopra VS; Segal E; Watanabe C; Haley B; Mayba O; Yaylaoglu M; Gnad F; Firestein R
J Clin Invest; 2016 Feb; 126(2):639-52. PubMed ID: 26752646
[TBL] [Abstract][Full Text] [Related]
39. BET bromodomain inhibitors block growth of pancreatic cancer cells in three-dimensional collagen.
Sahai V; Kumar K; Knab LM; Chow CR; Raza SS; Bentrem DJ; Ebine K; Munshi HG
Mol Cancer Ther; 2014 Jul; 13(7):1907-17. PubMed ID: 24807963
[TBL] [Abstract][Full Text] [Related]
40. Pharmacological Targeting of BET Bromodomains Inhibits Lens Fibrosis via Downregulation of MYC Expression.
Wang X; Wang B; Zhao N; Wang C; Huang M; Chen B; Chen J; Sun Y; Xiong L; Huang S; Liu Y
Invest Ophthalmol Vis Sci; 2019 Nov; 60(14):4748-4758. PubMed ID: 31731295
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
